Translating Nanotechnologies into Clinical Settings to Measure Response to Novel Cancer Agents: Nano Seminar Series

Seminar | December 1 | 2-3 p.m. | 180 Tan Hall | Note change in location

 Prof. Alice C. Fan, MD, Stanford University School of Medicine, Oncology

 Berkeley Nanosciences and Nanoengineering Institute

My laboratory studies how kinase inhibitors modulate protein signaling in patients with cancer. A barrier to this work has been the requirement for serial tumor samples from patients in order to measure changes in protein activation. To overcome this barrier, I use nanotechnologies to profile proteins in small numbers of patient tumor cells.

Our work addresses a series of questions at different levels. First, how can we robustly measure changes in proteins, the direct targets of kinase inhibitors, in our patients? I will discuss how we developed a novel nanoimmunoassay that can be used to profile changes in even single phosphorylations, in patient cells during therapy targeting kinase pathways. Second, do proteins measured in a single fine needle aspirate biopsy represent the whole tumor? We have begun to use nanoimmunoassays to characterize regional tumor heterogeneity in primary tumors. Third, can a less invasive approach to obtain tumor cells be developed?

I will discuss using nanotechnologies to isolate and analyze circulating tumor cells in a prospective clinical trial. At the end of the seminar, the audience will have knowledge of how nanotechnologies are being integrated into translational and clinical studies of targeted therapies for cancer.